What are the opening hours?

Monday 09:00 - 17:00 Tuesday 09:00 - 17:00 Wednesday 09:00 - 17:00 Thursday 09:00 - 17:00 Sunday 09:00 - 17:00

Medi World Middle East, Sharjah (2025)

10/07/2025

Movetru®, has closed a £1.2M Pre-Seed round led by Two Magnolias Venture Capital, with support from investors across the UK, Ireland, and the US.

Movetru’s wearable and AI-powered app delivers real-time biomechanical insights, helping athletes and coaches optimize performance and reduce injury risk. The funding supports Movetru’s European launch and commercial expansion.

Founder Naomi McGregor, inspired by her own injury experience, aims to make movement analysis accessible and actionable. The product is already used by sports organizations in the UK and Ireland, earning strong feedback for its validated, personalized assessments.

“We’re thrilled to lead this round for Movetru,” said Jessica Sue Rasmussen, Co-founder & CEO of Two Magnolias. “Naomi and her team tackle a key gap in sports performance with vision and ex*****on. Movetru showcases Northern Ireland’s top tech talent, and we’re excited to support them.”

“This round shows Movetru’s growing international recognition,” said Naomi McGregor, Founder & CEO. “With this investment, we’re accelerating our mission to empower athletes with better data—because when you understand movement, you can improve it.”

“Movetru gives me in-depth, actionable data on players’ movement in any environment,” said Stephen Key, Preformance Coach at the Belfast Giants. “Having this information in an easy-to-use format helps me make quick, informed decisions to support player and .”

09/07/2025

Real-Time Innovations (RTI), a leader in software frameworks for physical AI systems, has partnered with Kinova, a global robotics expert, to advance integration of robotics with data-centric connectivity.

This collaboration aims to simplify and accelerate product lifecycles, reduce risk, and drive innovation in advanced systems like surgical robotics. By integrating RTI Connext with Kinova’s platforms, the companies enable seamless design of next-gen solutions, connecting robotics with visualization, AI, and real-time data. Both firms are also part of NVIDIA’s Isaac for Healthcare program.

Their joint teleoperation demo, developed with MedAcuity, will be showcased at the Surgical Robotics Society Annual Meeting in Strasbourg, France.

François Boucher, VP of Business Development at Kinova:

"Kinova and RTI will accelerate the development of high-performance medical robotic systems. Combining Kinova’s surgical robotics with RTI’s real-time connectivity lets customers deliver next-gen solutions faster."

Bob Leigh, P.Eng, Senior Director at RTI:

"Customers face complex challenges in robotics, connectivity, and AI. This collaboration helps them innovate—whether in teleoperation, precision, or seamless integration."

08/07/2025

Aspivix has partnered with AGHealth to launch Carevix, an MHRA-approved non-traumatic suction cervical stabiliser, in the UK. This innovation offers a less painful, bleeding-reducing alternative to traditional tenaculum forceps during procedures like IUD and .

Peterborough City Hospital was the first UK site to adopt Carevix in 2024 under the Carevix Ambassador Program, involving 21 global centres. Results showed 96% clinician ease-of-use and 94% patient satisfaction.

The ADVANCE Women Study further confirmed Carevix reduces pain by 73% and bleeding by 78% versus standard tenaculums.

Charlotte Barker of AGHealth called Carevix a "dignified, pain-conscious option," while ASPIVIX CEO Mathieu Horras highlighted its potential to transform women’s healthcare. With MHRA approval, Carevix aims to address the fear of pain affecting millions during gynaecological procedures.

“At AGHealth, we focus on delivering forward-thinking, evidence-based solutions to clinicians. Carevix represents exactly the kind of innovation the UK market needs—offering a more dignified, pain-conscious option for gynaecological procedures that women undergo every day.”

Mathieu Horras, ASPIVIX CEO & Co-Founder added: “We are proud to bring Carevix to the UK in partnership with AGHealth, a company that shares our commitment to advancing women’s health through innovation. With MHRA approval and strong clinical results, Carevix provides a game-changing solution that improves both patient comfort and clinical confidence.”

03/07/2025

PathAI, a global leader in and digital pathology, has received FDA 510(k) clearance for AISight Dx, its digital pathology image management system, for primary diagnosis in clinical settings.

Building on its 2022 clearance for AISight Dx(Novo), this milestone highlights PathAI’s ongoing innovation. The FDA also approved a Predetermined Change Control Plan (PCCP), allowing PathAI to implement major updates—like new displays, scanners, and file formats—without additional 510(k) submissions, accelerating future enhancements.

AISight Dx streamlines workflows with intelligent case management, multi-slide navigation, and robust annotation tools, enabling faster, more consistent diagnoses and supporting high-quality patient care.

“Digital pathology empowers pathologists to work efficiently and collaborate without physical limitations,” said Andrew Beck, M.D., Ph.D., CEO of PathAI. “This 510(k) clearance demonstrates our commitment to quality and scientific rigor and enables us to keep improving AISight Dx.”

02/07/2025

Siemens AG has completed its $5.1 billion acquisition of Dotmatics, a leading Life Sciences R&D software provider, expanding Siemens’ AI-powered Xcelerator portfolio into the life sciences sector. Dotmatics will join Siemens’ Digital Industries Software business, enhancing its Product Lifecycle Management (PLM) offerings with a digital thread connecting research to production.

“With Dotmatics, we’re building a new era of innovation in Life Sciences,” said Roland Busch, Siemens CEO.

“We combine Dotmatics’ scientific intelligence with our industrial AI technologies and digital twins to help customers accelerate breakthroughs and bring life-saving pharmaceuticals faster and more affordably to market.”

The acquisition is expected to add over $300 million in revenue in fiscal 2025 and drive long-term growth, with medium-term revenue synergies of $100 million per year, accelerating to $500 million in the long term.

01/07/2025

Lilli Health, has launched the Lilli App—the first comprehensive platform using insulin management to reverse symptoms.

Backed by decades of research, the app provides at-home insulin testing, personalized meal plans, and real-time tracking to empower women with PCOS.

Key Features of the Lilli App:

1 - At-Home Insulin Testing – Track metabolic health with Lilli’s testing kits (rarely done in clinics).

2 - Personalized Meal Plans – Science-backed, insulin-friendly recipes tailored for PCOS.

3 - Symptom & Cycle Tracking – Log symptoms, ovulation, and irregular cycles with actionable insights.

4 - Lab Integration – Upload or test key markers (like insulin) and get easy-to-understand analysis.

5 - Expert-Backed Education – Learn how insulin resistance drives PCOS and how to reverse it.

Why It Matters:

1 - 1 in 5 women worldwide has PCOS, often misdiagnosed or given outdated advice.

2 - Insulin resistance is the root cause of PCOS symptoms (weight gain, infertility, acne).

3 - Traditional "eat less, exercise more" advice fails—Lilli’s approach targets insulin directly.

Dr. Ali Chappell, PhD, MS, RD, Lilli Health Founder (and PCOS patient):

"If you’re not lowering insulin, you’re not treating PCOS. Lilli gives women the tools to finally take control."

Dr. Steven Fleischman, MD, MBA, (Yale OB/GYN):

"Early insulin management can prevent long-term complications like obesity and diabetes."

Unlike generic PCOS apps, Lilli combines testing, education, and personalized care—like a dietitian in your pocket.

26/06/2025

Nerbio announces FDA 510(k) clearance for its iTOF® device, the world’s first wireless, app-controlled quantitative neuromuscular blockade (NMB) monitor.

Key features and benefits:

1 - Bluetooth-enabled nerve stimulator with mobile app.

2 - Supports TOF, PTC, and DBS stimulation modes.

3 - 10% faster operating room turnover.

4 - 30% reduction in neuromuscular blocker and reversal agent use.

5 - Up to 70% fewer residual blockade complications.

6 - AI-assisted, voice-guided prompts for enhanced decision-making.

7 - Cost-effective subscription at $1/day, eliminating disposables.

8 - Used in hospitals worldwide, improving patient safety and workflow efficiency.

“The FDA clearance of iTOF represents a significant advancement in neuromuscular monitoring,” said Henry Sullivant, Chief Executive Officer at Nerbio. “Our goal is to provide clinicians with accessible, accurate, and intelligent tools that enhance patient outcomes and streamline perioperative workflows.”

25/06/2025

Saudi-Emirati Global Fertility Network (GFN) has acquired a majority stake in HealthPlus Fertility Centers in Jeddah, rebranding it under Bnoon IVF, following its earlier acquisition of Bnoon IVF Center in Riyadh.

These deals, totaling over 100 million SAR ($27M), double GFN’s capacity to 5,000+ IVF cycles annually, making it Saudi Arabia’s largest stand-alone fertility provider. A 3,800m² flagship facility in Riyadh is set to open in December 2025. Backed by $60M in equity financing, including a 34.3% stake from Dubai Investments, GFN plans further expansion across the Kingdom, aiming to enhance access, technology, and clinical outcomes in line with Vision 2030.

“Our expansion in Saudi Arabia is central to GFN’s strategy to build a regional fertility and women’s health platform,” said Majd Abu Zant, Founder and CEO of Global Fertility Network. “With $60 million in equity financing and Dubai Investments acquiring a 34.3% stake, we are rapidly growing our network, planning new centers in , , and beyond, and accelerating access to advanced fertility care across the region.”

24/06/2025

That’s a Wrap on !

The Pan Arab Anesthesia Conference 2025 was an incredible success!

A huge thank you to all the brilliant minds, speakers, and attendees who made these three days in Dubai unforgettable. From cutting-edge insights to game-changing networking—what an event!

🔥 Key Takeaways from :

✔ Breakthroughs in pain management.

✔ New anesthesia tech & techniques.

✔ Unmatched networking with top experts.

Missed it? Don’t worry—we’ll be back!

What Was Your Highlight?

Was it the workshops? The keynote speeches? The networking?

Drop your favorite moment in the comments!

Relive the Magic of !

Check out our event photos & videos for a recap of the sessions, smiles and successes from MediworldME Team!

Photos credit goes to Deepu Raj

19/06/2025

Cleveland Clinic Abu Dhabi has become the first hospital in the to introduce continuous infusion therapy for advanced Parkinson’s disease, marking a major milestone in regional neurological care. The breakthrough treatment—administered via a compact, insulin-like pump—delivers steady medication to combat motor fluctuations, offering an alternative to deep brain stimulation (DBS).

A 51-year-old Emirati patient, who struggled with severe symptoms despite oral medication, has shown remarkable improvement post-treatment. "I finally have control over my life again," he shared, highlighting restored stability and quality of life.

Georges-Pascal Haber, CEO, emphasized the therapy’s role in addressing the rising global burden of Parkinson’s, while Shivam Om Mittal, MD noted its ease of use and reduced follow-up needs compared to DBS.

Dr. Georges-Pascal Haber, CEO:

"Our continuous infusion therapy marks a turning point for neurological care in the GCC. As Parkinson's cases rise, we're delivering personalized, cutting-edge solutions that redefine treatment standards and patient outcomes."

Dr. Shivam Om Mittal, Neurologist:

"This insulin-pump-style system provides 24/7 medication stability, transforming lives. Combined with DBS and oral therapies, we offer complete, tailored Parkinson's care - all supported by our specialized 24/7 team."*

With Parkinson’s cases projected to double by 2040, this innovation underscores the UAE’s commitment to cutting-edge, patient-centric healthcare.

Cleveland Clinic Abu Dhabi continues to lead with over 100 successful DBS surgeries since 2019 and now expands its arsenal with this transformative therapy.

18/06/2025

Gulf Scientific Corporation (GSC) has formed a strategic partnership with GeneMind Biosciences, a leader in sequencing, to enhance molecular diagnostics and prenatal care in the , , , and Qatar.

GeneMind’s cutting-edge non-invasive prenatal testing (NIPT) technology enables early, accurate detection of fetal chromosomal abnormalities, improving pregnancy outcomes.

Through this collaboration, GSC will leverage its regional expertise to introduce GeneMind’s innovative solutions, supporting healthcare providers with advanced diagnostics, research initiatives, and comprehensive after-sales services.

Manaf Afyouni, GSC Managing Director, stated, “This partnership aligns with our mission to deliver innovative healthcare solutions, revolutionizing prenatal care in the region.”

The alliance aims to drive scientific progress and improve patient outcomes through next-generation sequencing and precision medicine.

17/06/2025

Department of Health Abu Dhabi is leading a high-level delegation to the U.S. from June 14–21, 2025, reinforcing its leadership in healthcare innovation.

The mission, aligned with Abu Dhabi’s participation in BIO International Convention 2025, will visit , Washington D.C., and to showcase advancements in , , , and , as well as the HELM Life Science Cluster.

The delegation, including ADIO, Mubadala Bio, M42 Health, and PureHealth, will hold 20+ strategic meetings to foster partnerships, investment, and knowledge exchange. Abu Dhabi’s Emirati Genome Programme (800,000+ samples sequenced), 90+ research centers, and Malaffi (5M+ patient records) highlight its innovation ecosystem.

H.E. Dr. Noura AlGhaithi, DoH Undersecretary, emphasized collaboration to build a predictive, preventive, and curative healthcare system. Initiatives like the Golden Visa (2,000+ visas for global talent) further strengthen Abu Dhabi’s position as a life sciences hub.

Medi World Middle East

10/07/2025

09/07/2025

08/07/2025

03/07/2025

02/07/2025

01/07/2025

26/06/2025

25/06/2025

24/06/2025

19/06/2025

18/06/2025

17/06/2025

Address

Opening Hours

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Category

Monday	09:00 - 17:00
Tuesday	09:00 - 17:00
Wednesday	09:00 - 17:00
Thursday	09:00 - 17:00
Sunday	09:00 - 17:00